Human immune globulin infusion in Guillain‐Barré syndrome
Human immune globulin infusion in Guillain‐Barré syndrome
复制标题
人免疫球蛋白输注治疗吉兰-巴利综合征
作者：
L. H. Castro;A. Ropper
由于意外的高恶化率，我们报告了连续15例患者使用人免疫球蛋白（HIG）标准方案治疗格林-巴-罗综合征的结果。患者在出现首次症状后平均7天开始接受1.5 g/kg HIG治疗，持续4天。8名患者病情稳定或好转，但7名患者在治疗后5天内病情恶化，4名患者仍依赖呼吸机至少2.5个月。1例在治疗5周后严重复发。5例患者随后接受血浆置换，2例病情好转。我们的经验与以前支持HIG治疗格林-巴-罗综合征的报告不同。
Because of an unexpectedly high rate of worsening, we report the results of treatment of Guillain-Barré syndrome with a standard regimen of human immune globulin (HIG) in 15 consecutive patients. Patients were treated with 1.5 g/kg HIG for 4 days beginning a mean of 7 days after the first symptoms. Eight stabilized or improved, but seven deteriorated during or within the first 5 days after treatment, and four remained ventilator-dependent for at least 2.5 months. One had a severe relapse 5 weeks after treatment. Five patients subsequently received plasma exchange and two improved. Our experience varies from previous reports that have endorsed HIG treatment for Guillain-Barré syndrome.